Login to Your Account

Other News To Note

Tuesday, July 12, 2011
Poniard Pharmaceuticals Inc., of San Francisco, adjourned its annual meeting until July 22 to get additional proxies to approve a reverse stock split in the range of 1-for-15 to 1-for-25 to regain compliance with Nasdaq's minimum $1 bid requirement. If the proposal isn't approved, the company said it could impact completion of its merger agreement with privately held Allozyne Inc., of Seattle.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription